Trial Profile
The prospective study of the clinical efficacy/adverse event of regorafenib in unresectable metastatic and advanced colorectal cancer
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 27 Apr 2020
Price :
$35
*
At a glance
- Drugs Regorafenib (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms PEARC study
- 26 Apr 2020 Status changed from recruiting to discontinued.
- 17 Oct 2014 New trial record